Clover Biopharmaceuticals and Dynavax Technologies Corporation announced their plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted, with CpG 1018 plus alum in the first half of 2021.
In a press release on February 1, 2021, the companies stated an interim analysis for vaccine efficacy may become available in the middle of 2021.
Clover stated it expects to produce hundreds of millions of vaccine doses in 2021 and up to 1 billion vaccine doses in peak annual production as required by global demand.
Protein-based COVID-19 Vaccine Candidate Narrows Adjuvant Partner
NIH Launches Database to Study COVID-19-Related Neurological Complications
Clinicians are invited to submit data through an online portal
Maternal IgG Antibodies to SARS-CoV-2 Transferred Across Placenta
Positive correlation found for cord blood IgG concentrations with maternal IgG concentrations
Telemedicine Use Increased Considerably During COVID-19
Telemedicine use was lower in communities with higher rates of poverty; use varied across specialties, conditions
WHO Team Probing COVID-19 Origins Visits Wuhan Food Markets
Team’s visit has quickly become embroiled in politics, as China has sought to cast blame elsewhere for the emergence of COVID-19
U.S. Awards Contract for COVID-19 Home Test Kit
With the product from Australian company Ellume, users can swab themselves at home and check their status in about 20 minutes